Votum World, a Spanish startup based in Murcia and well-known for its work on health products made from CBD, has formally concluded its most recent round of funding, exceeding expectations and signaling a significant turning point in its development and innovation. The company raised €516,888 in total, surpassing its initial minimal target and solidifying its position in the biotechnology and wellness industry, according to a report from Murciaplaza.com.
Crowdfunding money
Startupxplore, a crowdfunding website designed to link entrepreneurs with investors, handled the investment round. The investment window officially ended on a Saturday at midnight, when the campaign came to a close. Votum raised €266,888 through Startupxplore alone, surpassing its €250,000 minimum investment goal and nearly reaching its €300,000 maximum goal.
Each of the 54 investors contributed an average of €5,176 to this campaign. Fifteen more potential investors showed interest on the platform. This indicates that the public views the brand positively. Votum extended the campaign by over two weeks and it exceeded the €240,000 milestone. The original deadline was March 23. The extension worked. It brought in an extra €20,000 and 11 more participants.
Votum had a successful crowdfunding campaign. They also raised an extra €250,000 through other means. This brings the total amount raised in this round to €516,888. The firm can expedite key goals. This includes research and development (R&D), team expansion, and strategic market outreach. This is possible due to the substantial capital infusion.
Murciaplaza.com states that product development will receive 40% of the entire funding, client acquisition will receive 30%, and market research will receive the remaining 30%. It is anticipated that these investments will strengthen Votum’s position in important industries and spur innovation.
The company’s participation in the European research project BIORCAN, a biotechnology project that seeks to create solutions that improve wellness, will also be strengthened by a share of the funding. Votum’s participation in the project demonstrates its dedication to scientific progress in the field of health and wellness, particularly in the creation of cannabidiol (CBD)-derived technologies.
Votum – business strategy
Votum, established in the Murcia region of Spain, employs a hybrid business strategy that combines online direct-to-consumer (B2C) platforms, business-to-business (B2B) clients, and physical distribution networks. The B2B market remains the most significant in terms of revenue and strategic importance, even with the multi-channel strategy in place. Since its founding, Votum has demonstrated remarkable financial growth. The company achieved revenues of €229,200 in 2024, marking a 34.5% increase from €170,400 in 2023. The firm tripled its income in just two years, earning €72,400 during its first full year of operation in 2022. The company’s quick growth leads to a premoney valuation of €2.7 million, a significant achievement for a startup in a highly regulated and competitive sector.
More than merely economic expansion, the success of this investment round indicates growing investor trust in the CBD wellness market and the promise of up-and-coming biotech companies from areas outside of Spain’s conventional startup hotspots. Murcia, which is frequently overlooked in the startup scene in favor of places like Madrid and Barcelona, is turning out to be a thriving hub for biotechnology and health innovation.
This round marks a significant advancement for Votum. The business is ready to expand and will intensify research and development. New funding and a clear plan support launching more advanced, scientifically backed products. Votum’s strategy and quick growth could place it at the forefront of this changing market. Consumer interest in CBD wellness is growing worldwide.
Votum World shows how local entrepreneurs can succeed. They use modern platforms and smart planning to exceed expectations. The business now has the resources to pursue ambitious goals. This includes product innovation, market expansion, and scientific research. The new capital of €516,888 will help achieve these objectives.